GIMV Aktie

 

Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease (AD) Financing was co-led by EQT Life Sciences out of its LSP Dementia Fund, together with Gimv, with participation from Fountain Healthcare......

Series B financing will support Exciva's Phase 2 clinical trial of its lead candidate, Deraphan, for agitation associated with Alzheimer's disease (AD) Financing was co-led by EQT Life Sciences out of its LSP Dementia Fund, together with Gimv, with participation from Fountain Healthcare......

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Gimv announced that it has reached an agreement to sell its majority stake in ALT Technologies to CCL Industries. No further financial details will be disclose......

Financing round led by RA Capital Management and Forge Life Science Partners, with contributions from new and existing investors Proceeds to advance frevecitinib, an inhaled pan-JAK inhibitor with the potential to treat the broad severe asthma population, through Phase 2 studiesBOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing a novel and differentiated inhaled therapeutic candidate to treat serious respiratory diseases, today announced the closing of a $103 million Series B financing. New investors RA Capital Management and Forge Life Science Partners led the financing, with participation from new investors EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital and existing investors, Atlas Venture, 5AM Ventures and Gimv. “Since day one, our goal has been to develop a best-in-class therapeutic for the treatment of severe inflammatory respiratory disease. Critically, and unlike the majorit...

ECM verkauft Intermate an Bridgepoint, Gimv investiert in den Pflegesektor und Apera legt einen 2,9 Milliarden Euro schweren Midmarket-Debt-Fonds auf: die spannendsten News aus der Private-Equity-Szene....